Johnson & Johnson's Pipeline-Driven Resilience: DARZALEX, CARVYKTI, and TREMFYA Fuel 10% Revenue Growth Amid STELARA Patent Cliff
核心洞察
Johnson & Johnson reported Q1 2026 revenue of $24.062 billion, a 9.9% year-over-year increase, with adjusted EPS of $2.70 beating consensus for the fourth consecutive quarter.
Pipeline assets DARZALEX, CARVYKTI, and TREMFYA posted explosive growth of 22.5%, 62.1%, and 68.3% respectively, absorbing the 59.7% revenue decline from STELARA's biosimilar erosion.
The company extended its dividend streak to 64 consecutive years with a 3.1% increase to $1.34 per share, backed by $19.7 billion in free cash flow for full-year 2025.
Johnson & Johnson (NYSE: JNJ) delivered first-quarter 2026 results that underscore the pharmaceutical and medical device giant's ability to weather patent cliffs while sustaining shareholder returns. The company posted revenue of $24.062 billion, reflecting 9.9% year-over-year growth, while adjusted earnings per share of $2.70 surpassed consensus estimates for the fourth consecutive quarter. Operating margin stood at 27.4%, with return on equity reaching 26.4%.
The performance arrives as J&J navigates a significant biosimilar challenge to one of its legacy blockbusters. STELARA revenue fell 59.7% in Q1 2026 to $656 million, a decline that would destabilize many pharmaceutical portfolios. Yet the company's pipeline is already absorbing the impact.
Pipeline Momentum Offsets Patent Losses
Three key growth drivers are reshaping J&J's Innovative Medicine portfolio. DARZALEX, the company's multiple myeloma (搜索) therapy, grew 22.5% in the quarter. CARVYKTI, a CAR-T cell therapy also targeting multiple myeloma, surged 62.1%. TREMFYA, indicated for psoriasis (搜索) and psoriatic arthritis (搜索), posted the strongest growth at 68.3%.
CEO Joaquin Duato characterized 2025 as a "catapult year," signaling confidence that the pipeline can sustain momentum through the end of the decade. Management raised full-year 2026 revenue guidance to a range of $100.3 billion to $101.3 billion, with a stated path to double-digit growth by decade's end.
A Balance Sheet Built for Durability
Johnson & Johnson remains one of only two U.S. public companies holding a AAA credit rating—a distinction that places its balance sheet above that of the U.S. government. The company generated $19.7 billion in free cash flow during full-year 2025, providing ample coverage for its long-standing dividend program.
In April, the board approved a 3.1% dividend increase to $1.34 per share, marking the 64th consecutive year of annual dividend increases—the longest streak of any healthcare company. The current annualized dividend of $5.20 yields approximately 2.33%, more than double the S&P 500 average. Quarterly payouts have climbed steadily from $1.01 in Q1 2021 to $1.34 in Q2 2026, uninterrupted through the 2008 financial crisis, the 2020 pandemic, and every recession in between.
Post-Kenvue Focus on High-Growth Sectors
Following the spin-off of its consumer products business, J&J now operates as a pure-play Innovative Medicine and MedTech company. Revenue is distributed across six priority areas: Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision. The stock's beta of 0.263 reflects the non-cyclical nature of healthcare demand—patients do not defer life-saving treatments based on market conditions.
The company's debt-to-equity ratio sits at approximately 0.7x, with interest costs covered 15 times over. The dividend payout ratio hovers around 60%, consistent with historical norms and suggesting no immediate risk to the distribution.
The Long View
Over the past decade, J&J's revenues have grown at an annualized rate of 3%, while earnings have expanded at roughly 7%. The dividend compounded at approximately 6% annually over the same period, outpacing long-term inflation. Patent cliffs, as the STELARA case illustrates, are recurring events for a pharmaceutical enterprise of this scale. The company has navigated every previous cycle by replacing lost revenue with new approvals—a pattern that the current growth trajectory of DARZALEX, CARVYKTI, and TREMFYA appears poised to repeat.